Stock Events

Stock Events

Search...

Madrigal Pharmaceuticals

$210.47

32

-$5.13-2.38% Thursday 20:00

Statistics

Day High

216.66

Day Low

208.53

52W High

299.98

52W Low

119.76

Volume

218,222

Avg. Volume

271,398

Mkt Cap

5.37B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

6NovExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-7.54

-6.43

-5.33

-4.23

Expected EPS

-7.048399

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MDGL. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Viking Therapeutics

Viking Therapeutics is developing therapies for metabolic and endocrine disorders, directly competing with Madrigal's NASH treatments.

Gilead Sciences

Gilead Sciences has a strong focus on liver diseases, including NASH, positioning it as a competitor in the same therapeutic area as Madrigal.

Galmed Pharmaceuticals

Galmed Pharmaceuticals is developing treatments for liver diseases, including NASH, making it a direct competitor to Madrigal.

Agios Pharmaceuticals

Agios Pharmaceuticals focuses on metabolic disorders, competing in the same space as Madrigal's treatments for liver diseases.

FibroGen is involved in the discovery and development of therapies for liver diseases, including NASH, competing with Madrigal.

Axsome Therapeutics

Axsome Therapeutics, while primarily focused on CNS disorders, has interests in metabolic disorders, potentially putting it in competition with Madrigal.

Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for liver diseases, making it a potential competitor to Madrigal in the NASH space.

Analyst Ratings

309.33$Average Price Target

The highest estimate is $390.

From 8 ratings within the last 6 months. This is not an investment recommendation.

Buy

50%

Hold

38%

Sell

13%

About

Health Technology

Pharmaceuticals: Other

Manufacturing

Pharmaceutical Preparation Manufacturing

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Show more...

CEO

Rebecca Taub

Employees

376

Country

US

ISIN

US5588681057

Listings